[Fluoxetine in the treatment of borderline personality disorder].

Actas luso-espanolas de neurologia, psiquiatria y ciencias afines Pub Date : 1997-11-01

H Silva, S Jerez, A Paredes, J Salvo, P Rentería, A Ramírez, C Montes

{"title":"[Fluoxetine in the treatment of borderline personality disorder].","authors":"H Silva, S Jerez, A Paredes, J Salvo, P Rentería, A Ramírez, C Montes","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: This study evaluates the therapeutic effect of fluoxetine, a selective serotonin reuptake inhibitor, in borderline personality disorder.Method: 46 patients with borderline personality disorder according to DSM-III-R and Diagnostic Interview for Borderlines (DIB-R) criteria, were given fluoxetine 20-60 mg for seven weeks. They were evaluated each week using Brief Psychiatric Rating Scale (BPRS), Global Assessment of Functioning Scale (GAF), Hamilton Depression Rating Scale (HDRS) and a clinical Impulsivity Scale.Results: There were significant improvements in BPRS, HDRS, GAF and Impulsivity Scale from the first week of the treatment. These improvements continued until the seven week of treatment. The favourable outcome was not only due to the improvement in depression and impulsivity scores, but also to the decline of global psychopathology.Conclusions: The data suggest that fluoxetine is an effective pharmacologic treatment for borderline personality disorder. These findings support the hypothesis of a 5-HT dysfunction in borderline personality disorder.","PeriodicalId":75429,"journal":{"name":"Actas luso-espanolas de neurologia, psiquiatria y ciencias afines","volume":"25 6","pages":"391-5"},"PeriodicalIF":0.0000,"publicationDate":"1997-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas luso-espanolas de neurologia, psiquiatria y ciencias afines","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study evaluates the therapeutic effect of fluoxetine, a selective serotonin reuptake inhibitor, in borderline personality disorder.

Method: 46 patients with borderline personality disorder according to DSM-III-R and Diagnostic Interview for Borderlines (DIB-R) criteria, were given fluoxetine 20-60 mg for seven weeks. They were evaluated each week using Brief Psychiatric Rating Scale (BPRS), Global Assessment of Functioning Scale (GAF), Hamilton Depression Rating Scale (HDRS) and a clinical Impulsivity Scale.

Results: There were significant improvements in BPRS, HDRS, GAF and Impulsivity Scale from the first week of the treatment. These improvements continued until the seven week of treatment. The favourable outcome was not only due to the improvement in depression and impulsivity scores, but also to the decline of global psychopathology.

Conclusions: The data suggest that fluoxetine is an effective pharmacologic treatment for borderline personality disorder. These findings support the hypothesis of a 5-HT dysfunction in borderline personality disorder.

本刊更多论文

[氟西汀治疗边缘型人格障碍]。

目的:评价选择性5 -羟色胺再摄取抑制剂氟西汀治疗边缘型人格障碍的疗效。方法:46例边缘型人格障碍患者符合DSM-III-R和边缘型人格障碍诊断访谈(DIB-R)标准，给予氟西汀20 ~ 60 mg，疗程7周。他们每周使用简短精神病学评定量表(BPRS)、整体功能评定量表(GAF)、汉密尔顿抑郁评定量表(HDRS)和临床冲动量表进行评估。结果:患者的BPRS、HDRS、GAF、冲动性量表较治疗第一周有明显改善。这些改善一直持续到治疗的第七周。良好的结果不仅是由于抑郁和冲动得分的改善，而且还由于整体精神病理学的下降。结论:氟西汀是治疗边缘型人格障碍的有效药物。这些发现支持了边缘型人格障碍患者存在5-羟色胺功能障碍的假设。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Actas luso-espanolas de neurologia, psiquiatria y ciencias afines

自引率

0.00%

发文量